Facilitating prediction of adverse drug reactions by using knowledge graphs and multi-label learning models
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Timely identification of adverse drug reactions (ADRs) is highly important in the domains of public health and pharmacology. Early discovery of potential ADRs can limit their effect on patient lives and also make drug development pipelines more robust and efficient. Reliable in silico prediction of ADRs can be helpful in this context, and thus, it has been intensely studied. Recent works achieved promising results using machine learning. The presented work focuses on machine learning methods that use drug profiles for making predictions and use features from multiple data sources. We argue that despite promising results, existing works have limitations, especially regarding flexibility in experimenting with different data sets and/or predictive models. We suggest to address these limitations by generalization of the key principles used by the state of the art. Namely, we explore effects of: (1) using knowledge graphs-machine-readable interlinked representations of biomedical knowledge-as a convenient uniform representation of heterogeneous data; and (2) casting ADR prediction as a multi-label ranking problem. We present a specific way of using knowledge graphs to generate different feature sets and demonstrate favourable performance of selected off-the-shelf multi-label learning models in comparison with existing works. Our experiments suggest better suitability of certain multi-label learning methods for applications where ranking is preferred. The presented approach can be easily extended to other feature sources or machine learning methods, making it flexible for experiments tuned toward specific requirements of end users. Our work also provides a clearly defined and reproducible baseline for any future related experiments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Introduction to Information Retrieval
Manning, C. D., Raghavan, P., & Schütze, H. (2008) · doi:10.1017/cbo9780511809071 · Cited by 11,288
KEGG: new perspectives on genomes, pathways, diseases and drugs
Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y., & Morishima, K. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1092 · Cited by 8,865
The relationship between Precision-Recall and ROC curves
Davis, J., & Goadrich, M. (2006) · Proceedings of the 23rd international conference on Machine learning - ICML '06 · doi:10.1145/1143844.1143874 · Cited by 6,559
PubChem Substance and Compound databases
Kim, S., Thiessen, P. A., Bolton, E. E., Chen, J., Fu, G., Gindulyte, A., Han, L., He, J., He, S., Shoemaker, B. A., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv951 · Cited by 5,436 · cited 1×
“PubChem Compound data [31] contains chemical structure description of drugs.”
BackgroundCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Drug target identification using side-effect similarity
Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P. (2008) · Science · doi:10.1126/science.1158140 · Cited by 1,248 · cited 2×
“Most state-of-the-art techniques adopt a drug-centric approach and rely on the assumption that similar drugs share the same properties, mechanism of action and therefore also ADRs [15, 16].”
BackgroundMethodReducing safety-related drug attrition: the use of in vitro pharmacological profiling
Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., & Whitebread, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3845 · Cited by 748 · cited 1×
“pharmacology profiling leads to the identification of potential drug-induced biological system perturbations including primary effects (intended drug–target interactions) as well as secondary effects (off-target–drug interactions) mainly responsible for ADRs [1].”
BackgroundA curated and standardized adverse drug event resource to accelerate drug safety research
Banda, J. M., Evans, L., Vanguri, R. S., Tatonetti, N. P., Ryan, P. B., & Shah, N. H. (2016) · Scientific Data · doi:10.1038/sdata.2016.26 · Cited by 246
An integrative machine learning approach for prediction of toxicity-related drug safety
Lysenko, A., Sharma, A., Boroevich, K. A., & Tsunoda, T. (2018) · Life Science Alliance · doi:10.26508/lsa.201800098 · Cited by 88
Cited by
Machine Learning Methods for Small Data Challenges in Molecular Science
Dou, B., Zhu, Z., Merkurjev, E., Ke, L., Chen, L., Jiang, J., Zhu, Y., Liu, J., Zhang, B., & Wei, G.-W. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00189 · Cited by 499
Toward better drug discovery with knowledge graph
Zeng, X., Tu, X., Liu, Y., Fu, X., & Su, Y. (2022) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2021.09.003 · Cited by 229
An integrative machine learning approach for prediction of toxicity-related drug safety
Lysenko, A., Sharma, A., Boroevich, K. A., & Tsunoda, T. (2018) · Life Science Alliance · doi:10.26508/lsa.201800098 · Cited by 88
Zhou, H., Cao, H., Matyunina, L., Shelby, M., Cassels, L., McDonald, J. F., & Skolnick, J. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01248 · Cited by 39
Protein kinase inhibitors as therapeutics in neurodegenerative and psychiatric disorders
Tridente, G., Jana, A., Nath, A., & Ashraf, G. M. (2023) · Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders · doi:10.1016/b978-0-443-18677-6.00015-4 · Cited by 8
Metadata
- Authors
- Muñoz, E., Nováček, V., & Vandenbussche, P.-Y.
- Venue
- Briefings in Bioinformatics
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-08-18
- Volume
- 20
- Issue
- 1
- Pages
- 190-202
- ISSN
- 1467-5463 (ISSN-L)
- 1477-4054
- OpenAlex
- W2746873727
- Cited by
- 76
- References
- 9
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.